PVX 410

Drug Profile

PVX 410

Alternative Names: PVX-410; XBP1-US/XBP1-SP/CD138/CS1 multipeptide vaccine PVX-410

Latest Information Update: 30 Nov 2016

Price : $50

At a glance

  • Originator Dana-Farber Cancer Institute
  • Developer AstraZeneca; Emory University; Massachusetts General Hospital; OncoPep
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Multiple myeloma
  • Phase I Breast cancer

Most Recent Events

  • 28 Nov 2016 Efficacy and safety data from a phase I/IIa trial in Multiple myeloma released by OncoPep
  • 28 Nov 2016 OncoPep, Celgene and Massachusetts General Hospital initiate a phase Ib trial for Multiple Myeloma (Combination therapy) in USA (NCT02886065)
  • 31 Aug 2016 OncoPep, Celgene and Massachusetts General Hospital plan a phase Ib trial for Multiple Myeloma (Combination therapy) in USA (NCT02886065)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top